Chinese firms have expressed interest to produce an investigational Covid-19 drug developed by US pharmaceutical companies Merck and Ridgeback Biotherapeutics – under a global programme for their distribution in developing countries.
The UN-backed Medicines Patent Pool (MPP) recently reached an agreement with Merck to grant sublicences for other pharmaceutical firms to produce generic versions of the experimental molnupiravir antiviral pill, for supply to 105 middle- and low-income countries. And Chinese companies are among applicants seeking the royalty-free sublicences.
Already a subscriber? Log in.
Limited time offer:
Just RM5 per month.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!
